Shaun Kilty profile picture

Contact Information

Shaun Kilty, MD,FRCSC
613-798-5555 xt. 18514

Fax: 613-729-2412

Research Activities

Endoscopic Polypectomy In Clinic (EPIC) is a recently developed, deescalated form of endoscopic sinus surgery (ESS) performed in the Outpatient Clinic instead of the Operating Room for patients with chronic rhinosinusitis with polyps. EPIC represents a potentially disruptive innovation requiring rigorous evaluation before its widespread adoption. We are currently working on a non-inferiority trial that will allow us to determine  if EPIC is as effective as the current standard of care ESS.  For this project Dr. Kilty has received a CIHR grant through the  Project Grant Competition.
PEPIS STUDY (Posterior Epistaxis Study)

This work  includes the 2014 trial publication using a commercially available hemostatic agent, Floseal, to treat posterior epistaxis, a common and severe form of nosebleed. It was published in one of the leading Otolaryngology journals, The Laryngoscope. This trial showed Floseal to be a highly effective treatment that was associated with significant cost savings (up to $4500 or 89% per case) in comparison to currently available treatments. This procedure allows an affected patient to be discharged home from the emergency department within 2 hours of being treated rather than being admitted to hospital for up to 3 days. Although the full impact of this work is yet to be realized given it has only just been published, the dissemination of the findings has already lead to a change in the first line treatment for patients with posterior epistaxis at my institution.

Further evidence of innovation in rhinology includes the early work that I, and my group, completed evaluating manuka honey as both an antimicrobial and anti-inflammatory treatment for chronic rhinosinusitis. We identified the in vitro dose of manuka honey that was ideal for use as an antimicrobial and anti-biofilm treatment agent. Using this dose in an animal model, we then demonstrated that manuka honey is a safe treatment for the respiratory mucosa of the nose and paranasal sinuses. Further, we identified a component of manuka honey, methylglyoxal, to have potent antibacterial and anti-biofilm properties.

Recent published activity in methodological research has evaluated the best treatment for patients with a sinus tumor called hemangiopericytoma. This was published in one of the highest-ranking Otolaryngology journals, Head & Neck. It provides clear evidence based guidance for Otolaryngologists on how to best treat these tumors and it demonstrated that minimally invasive endoscopic surgical approaches were clearly supported in the hands of surgeons with this skillset. As an academic surgeon at the Ottawa Hospital and the University of Ottawa, I continue to look to improve the quality of care that I, and my rhinology colleagues, provide by evaluating potential treatments with clinical trials while also evaluating and testing the literature to better define treatment effects and to overcome deficiencies in knowledge.